- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 17, 2024Emily Tremblay Named IP Rising Star by Euromoney in 2024 Women in Business Law Awards
-
June 17, 2024Three Robins Kaplan Partners Named BTI Client Service All-Stars
-
June 13, 2024Brendan Johnson Named South Dakota Trial Lawyer of The Year
-
June 27, 2024Sex Abuse Litigation
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
June 11, 2024FBA 2024 Federal Practice Seminar
-
June 2024Robins Kaplan Secures Landmark $7.75 Million Verdict in Aerosol Duster Misuse Case
-
June 2024To Seize or Not to Seize: Campus Protests and Police Uses of Force
-
June 2024Communicating Your Estate Plan: A Helpful Tool, Not a Fix-All
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Novartis Pharms. Corp. v. Alembic Pharms. Ltd.
Entresto® (sacubitril/valsartan)
September 29, 2023
![GENERICally Speaking](/-/media/images/newsletters/generically-speaking-social-graphics/generic_390x160.png?la=en&h=160&w=390&la=en&hash=7C4F410F9639FA5CC4261D8C8A36AB07)
Case Name: Novartis Pharms. Corp. v. Alembic Pharms. Ltd., Civ. No. 22-1395-RGA, 2023 WL 6387975 (D. Del. Sept. 29, 2023) (Andrews, J.)
Drug Product and Patent(s)-in-Suit: Entresto® (sacubitril/valsartan); U.S. Patent No. 11,096,918 (“the ’918 patent”)
Nature of the Case and Issue(s) Presented: Previously, Novartis sued Noratech, MSN, and other defendants, alleging that each defendant’s ANDA products infringed various patents. As part of that previous litigation, Noratech and MSN provided to Novartis their ANDAs, product samples, and other confidential information subject to the protective order entered in that case. Novartis ultimately dismissed its infringement claims.
Novartis then filed this case asserting, “on information and belief,” that Noratech’s and MSN’s ANDA products (the same ANDA products accused in the previous case) infringe the ’918 patent. Noratech filed a motion to dismiss for failure to state a claim, and the MSN defendants filed a motion for judgment on the pleadings. Defendants argued that Novartis’s “on information and belief” allegations were insufficient, and that Novartis should have to plead infringement with greater specificity based on ANDAs, testing data, and other documents it obtained during the previous litigation. The court denied both motions.
Why Novartis Prevailed: The court had previously interpreted the protective order governing Defendants’ disclosures in the previous litigation as preventing use of that information to initiate other litigation. Thus, Novartis could not plead infringement with the additional detail that Defendants demanded. Moreover, the court reaffirmed application of the more “relaxed” Belcher pleading standard in ANDA infringement cases, including those asserting only non-OB-listed patents, like this one—ANDA infringement plaintiffs are held to a lower level of specificity than plaintiffs in other patent infringement cases.
MSN also moved for judgment of non-infringement, arguing that the ’918 patent claims an amorphous form of the claimed compound and its ANDA product requires a crystalline form. Consistent with recent trends, the court determined that it could not adjudicate infringement at this early stage—in particular, without expert testimony—and pleading that the ANDA product infringes was sufficient. The court went so far as to state that “an ANDA does not provide a complete answer to infringement.”
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.